Junli Xue

683 total citations · 1 hit paper
26 papers, 434 citations indexed

About

Junli Xue is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Junli Xue has authored 26 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Junli Xue's work include Cancer Immunotherapy and Biomarkers (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and HER2/EGFR in Cancer Research (5 papers). Junli Xue is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and HER2/EGFR in Cancer Research (5 papers). Junli Xue collaborates with scholars based in China, United States and Chile. Junli Xue's co-authors include Wei Zhao, Xiaoxiao Ge, Liqiong Xue, Shan Zhang, Yan Huang, Kun Ling, Chunhua Chen, Manlong Qi, Haidong Dong and Shu‐Heng Jiang and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancer Letters.

In The Last Decade

Junli Xue

25 papers receiving 428 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

2024 87 citations Qing Wei, Peijing Li et al. Journal of Hematology & Oncology profile →

Peers

Junli Xue

ONCOL

IMMUN

PRM

RNMI

Luisa M. Solis Soto United States

Carlo Fremd Germany

Anna F. Piotrowski United States

Stephan Seitz Germany

Faith Nutter United Kingdom

Yawen Ju United States

Barbara O’Brien United States

Miklós Gulyás Sweden

Christine Lu‐Emerson United States

Jethro Hu United States

Luisa M. Solis Soto United States

Junli Xue

270 ×1.1

ONCOL

113 ×1.0

169 ×2.1

IMMUN

80 ×1.2

PRM

21 ×0.4

RNMI

Citations per year, relative to Junli Xue Junli Xue (= 1×) peers Luisa M. Solis Soto

Countries citing papers authored by Junli Xue

Since Specialization

Citations

This map shows the geographic impact of Junli Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junli Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junli Xue more than expected).

Fields of papers citing papers by Junli Xue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junli Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junli Xue. The network helps show where Junli Xue may publish in the future.

Co-authorship network of co-authors of Junli Xue

This figure shows the co-authorship network connecting the top 25 collaborators of Junli Xue. A scholar is included among the top collaborators of Junli Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junli Xue. Junli Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Mei, Na Wang, Xuebing Jia, et al.. (2025). CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype. Journal of Experimental & Clinical Cancer Research. 44(1). 113–113. 2 indexed citations

Xue, Junli, Yunchao Liu, Boyan Liu, et al.. (2024). Celastrus orbiculatus Thunb. extracts and celastrol alleviate NAFLD by preserving mitochondrial function through activating the FGF21/AMPK/PGC-1α pathway. Frontiers in Pharmacology. 15. 1444117–1444117. 5 indexed citations

Xue, Junli, Yan Zhang, Xudong Hu, et al.. (2024). Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e14694–e14694. 2 indexed citations

Guo, Ye, Lihua Wu, Yong Li, et al.. (2024). First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2662–2662. 3 indexed citations

Wang, Hao, et al.. (2024). Schwann cells and enteric glial cells: Emerging stars in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(5). 189160–189160. 8 indexed citations

Wei, Qing, Peijing Li, Teng Yang, et al.. (2024). The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. Journal of Hematology & Oncology. 17(1). 1–1. 87 indexed citations breakdown →

Xue, Junli, Liqiong Xue, Wenbo Tang, et al.. (2024). TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Therapeutic Advances in Medical Oncology. 16. 2665252–2665252. 3 indexed citations

Xue, Liqiong, Wenbo Tang, Junli Xue, et al.. (2023). Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors. Frontiers in Oncology. 13. 1276009–1276009. 6 indexed citations

Li, Lanfang, et al.. (2023). Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients. Frontiers in Endocrinology. 14. 1140196–1140196. 11 indexed citations

10.

Wang, Hao, Cheng Li, Shan Zhang, et al.. (2023). Perineural invasion in colorectal cancer: mechanisms of action and clinical relevance. Cellular Oncology. 47(1). 1–17. 43 indexed citations

11.

Li, Qun, Ye Guo, Junli Xue, et al.. (2023). Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e15001–e15001. 1 indexed citations

12.

Jiang, Shu‐Heng, Shan Zhang, Hao Wang, Junli Xue, & Zhigang Zhang. (2022). Emerging experimental models for assessing perineural invasion in human cancers. Cancer Letters. 535. 215610–215610. 36 indexed citations

13.

Guo, Ye, Wenbo Tang, Fengjuan Lin, et al.. (2022). Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF/FGFR gene aberrations.. Journal of Clinical Oncology. 40(16_suppl). 6039–6039.

14.

Chen, Chunhua, Junli Xue, Manlong Qi, et al.. (2021). PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. JCI Insight. 6(8). 58 indexed citations

15.

Guo, Yin, Junli Xue, Xue Li, et al.. (2021). 271P First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors. Annals of Oncology. 32. S480–S481. 8 indexed citations

16.

Tang, Qinghe, Wei Huang, Jun Liang, & Junli Xue. (2021). Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. Frontiers in Oncology. 11. 646410–646410. 5 indexed citations

17.

Rodón, Jordi, J. Li, Junli Xue, et al.. (2021). 514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors. Annals of Oncology. 32. S585–S585. 11 indexed citations

18.

Li, Jin, Ye Guo, Junli Xue, et al.. (2020). First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS1101–TPS1101. 17 indexed citations

19.

Shen, Tingting & Junli Xue. (2019). Impact of a novel ultrasound microvascular imaging and elastography on prostate cancer classification. Translational Andrology and Urology. 8(6). 696–702. 6 indexed citations

20.

Xue, Junli, Victoria K. Xie, Pei Wang, et al.. (2014). Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs. Current Pharmaceutical Design. 20(33). 5298–5308. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact